Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 1, Open-Label, Dose Escalation Study of CLR 131 in Children and Adolescents with Select Solid Tumors, Lymphoma, and Malignant Brain Tumors
Protocol ID
DCL-17-001
Disease (Sub Disease)
Various
Diagnosis Stage
Relapsed
Refractory
Recurrent
Refractory
Recurrent
Sponsor
Cellectar Biosciences, Inc.
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1
Age Eligibility
2 Years to 25 Years
International registry ID's
NCT03478462
| Study Title | A Phase 1 Open-Label Dose Escalation Study of CLR 131 in Children and Adolescents with Select Solid Tumors Lymphoma and Malignant Brain Tumors |
|---|---|
| Protocol ID | DCL-17-001 |
| Disease (Sub Disease) | Various |
| Diagnosis Stage | Relapsed Refractory Recurrent |
| Sponsor | Cellectar Biosciences, Inc. |
| Links | https://clinicaltrials.gov/ct2/show/NCT03478462 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 30/04/2019 |
| Study Type | Treatment |
| Phase | Phase 1 |
| Age Eligibility | 2 Years to 25 Years |
| International registry ID's | NCT03478462 |